Neuroendocrine Tumours – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. Report Overview

2. Neuroendocrine Tumours - Overview

3. Executive Summary

4. Neuroendocrine Tumours : Pipeline Assessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3. By Drug Class

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. Neuroendocrine Tumours: Company & Drug Profiles

5.1. Clinical Stage

5.1.1. Sulfatinib – Hutchison Medipharma Limited.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. XmAb18087 – Xencor, Inc.

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. Humanized anti-PD-1 monoclonal antibody – Shanghai Junshi Biosciencee Co.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Neuroendocrine Tumours: An Overview on Dormant & Discontinued Pipeline Candidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. Neuroendocrine Tumours: Additional Key Insights

7.1. Epidemiology Overview: Neuroendocrine Tumours

7.2. Current Market Scenario: Neuroendocrine Tumours Therapeutics

8. Neuroendocrine Tumours: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.